Efficacy of β2-agonist and Impratropium Bromide in Chronic Obstructive Pulmonary Disease

胡洁,洪群英,白春学

DOI: https://doi.org/10.3969/j.issn.1672-8467.2002.04.023

2002-01-01

Abstract:Purpose: To compare the efficacy and safety of β2-agonist and impratropium bromide incombination vs either agent alone in chronic obstructive pulmonary disease (COPD). Methods: 60 patients with acute exabration of COPD were randomized into 3 groups. Each group received 2.0 mL of inhaled 0. 025% impratropium bromide, 0.25 mL of inhaled 0.5% fenoterol Hbr or 2. 5 mL of inhaled impratropium bromide plus salbutamol sulfate. Lung funtion was assessed before drug administration and 20,40,60,120 min thereafter. At the end of 2 h period, each patient received blood gas analysis. Results: All three groups significantly improved in FEV1% FVC compared with baseline. Combination treatment with salbutamol sulfate plus impratropium bromide provided significantly (P < 0. 05) greater improvements in polmonary function and the efficacy lasted longer than bronchodilators given alone. Conclusions: Patients with acute exabration of COPD may benefit from combination treatment with beta2-agonist plus impratropium bromide without a resulting increase in adverse events.